The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 07, 2017

Filed:

Dec. 18, 2015
Applicants:

The Regents of the University of California, Oakland, CA (US);

Schepens Eye Research Institute, Boston, MA (US);

Inventors:

Benjamin Sullivan, San Diego, CA (US);

Tannin A. Schmidt, Calgary, CA;

David A. Sullivan, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/14 (2006.01); A61K 9/00 (2006.01); A61K 31/568 (2006.01); A61K 31/715 (2006.01); A61K 38/13 (2006.01); A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 31/728 (2006.01); A61K 31/685 (2006.01); A61K 31/688 (2006.01); A61K 47/02 (2006.01); A61K 47/24 (2006.01);
U.S. Cl.
CPC ...
A61K 38/14 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 31/568 (2013.01); A61K 31/685 (2013.01); A61K 31/688 (2013.01); A61K 31/715 (2013.01); A61K 31/728 (2013.01); A61K 38/13 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/1841 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/24 (2013.01);
Abstract

The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.


Find Patent Forward Citations

Loading…